Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)

BACKGROUND: Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD). METHODS: This randomized, open-label, active-controlled Phase 3 study compared roxadustat versus darbepoetin alfa (DA) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Barratt, Jonathan, Andric, Branislav, Tataradze, Avtandil, Schömig, Michael, Reusch, Michael, Valluri, Udaya, Mariat, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396401/
https://www.ncbi.nlm.nih.gov/pubmed/34077510
http://dx.doi.org/10.1093/ndt/gfab191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396401/
https://www.ncbi.nlm.nih.gov/pubmed/34077510
http://dx.doi.org/10.1093/ndt/gfab191

Ejemplares similares